What moved HCWB stock pre market on 17 Mar 2026?

HCWB stock jumped after a Science Advances paper and company release showed HCW9206 improved CAR-T production and persistence. Heavy volume and trader attention pushed intraday prices higher, but clinical validation is still required.

What is Meyka AI's rating and how is it calculated?

Meyka AI rates HCWB **66.71/100** (Grade B, HOLD). The score aggregates S&P 500 and sector comparisons, industry metrics, financial growth, key ratios, forecasts, and analyst signals. This is informational and not investment advice.

What are realistic price targets for HCWB stock?

Meyka AI's 12-month model target is **USD 3.7801** (implied +304.30%). A conservative near-term target could be **USD 1.50** (+60.42%). Forecasts are model-based projections and not guarantees.

What risks should investors watch with HCW Biologics?

Main risks: preclinical-to-clinical translation, limited cash (current ratio ~0.06), microcap liquidity, and potential dilution from fundraising. Positive preclinical data may not lead to revenue or successful trials.

US Stocks

HCWB HCW Biologics (NASDAQ) +81% pre market 17 Mar 2026: CAR-T paper lifts volume

ByHuzaifa Zahoor March 17, 2026March 17, 2026

HCWB stock opened the pre market session on 17 Mar 2026 after an 81.19% jump to $0.9351 on heavy activity, making HCW Biologics Inc. (NASDAQ) one of the most active names in the United States healthcare market. Volume spiked to 457,205,436 shares versus an average of 110,558, reflecting headline-driven trading after a Science Advances paper and company release. We review why the CAR-T manufacturing results moved prices, the company’s fragile financials, and what traders should watch into the April earnings print and short-term technicals.